Author of

• 20195

  +

  P3.16 - Surgery (ID 732)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: Surgery
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/18/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)

  • 24239

    +

    P3.16-016 - Prognosis of Patients with Remnant Tumor at Bronchial Stump After Pulmonary Resection for NSCLC: Based on Case Series Study (ID 9939)

    09:30 - 09:30  |  Author(s): H. Kim
    • Abstract

    Background:
    Current guidelines recommend adjuvant therapy for positive margins after surgical resection. However, there is no strong evidence for those adjuvant therapies. In this study, we analyzed series of patients with microscopically tumor-positive bronchial stump (R1) and compared it with patients with complete R0 resection.
    
    Method:
    From 2011 to 2015, 172 patients underwent surgical treatment for NSCLC at out center. Excluding three patients with pleural seeding and residual tumors at parenchymal resection margin, 10 patients were bronchial R1 resection. We performed a retrospective analysis of patients’ data during follow-up (mean 36.6 months).
    
    Result:
    All patients with R1 disease received adjuvant therapies. Mode of adjuvant therapy was not related to recurrence (P=0.683) within R1 group. Kaplan-Meier analysis showed that recurrence rate in R1 group was higher compared to R0 resection group (P=0.001) when no stratification for staging was done. However, overall survival was not different between two groups (P=0.087). Figure 1 Figure 2
    
    
    
    
    
    Conclusion:
    In this study, R1 resection group was revealed as a risk factor for tumor recurrence while it did not significantly affect overall survival. The type of adjuvant therapy had no relation to the recurrence of NSCLC. But further investigation with large cohort is necessary to find out the exact effect of adjuvant therapy and stage.